Integrating the clinical pharmacist into the emergency department interdisciplinary team: A study protocol for a multicentre trial applying a non-randomised stepped-wedge study design
Introduction: The ‘emergency department (ED) pharmacist’ is an integrated part of the ED interdisciplinary team in many countries, which have shown to improve medication safety and reduce costs related to hospitalisations. In Norway, few EDs are equipped with ED pharmacists, and research describing...
Gespeichert in:
Veröffentlicht in: | BMJ open 2021 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction: The ‘emergency department (ED) pharmacist’
is an integrated part of the ED interdisciplinary team in many
countries, which have shown to improve medication safety and
reduce costs related to hospitalisations. In Norway, few EDs are
equipped with ED pharmacists, and research describing effects
on patients has not been conducted. The aim of this study is
to investigate the impact of introducing clinical pharmacists
to the interdisciplinary ED team. In this multicentre study, the
intervention will be pragmatically implemented in the regular
operation of three EDs in Northern Norway; Tromsø, Bodø
and Harstad. Clinical pharmacists will work as an integrated
part of the ED team, providing pharmaceutical care services
such as medication reconciliation, review and/or counselling.
The primary endpoint is ‘time in hospital during 30 days after
admission to the ED’, combining (1) time in ED, (2) time in
hospital (if hospitalised) and (3) time in ED and/or hospital if
re-hospitalised during 30 days after admission. Secondary
endpoints include time to rehospitalisation, length of stay in ED
and hospital and rehospitalisation and mortality rates.
Methods and analysis: We will apply a nonrandomised stepped-wedge study design, where we
in a staggered way implement the ED pharmacists in
all three EDs after a 3, 6 and 9 months control period,
respectively. We will include all patients going through
the three EDs during the 12-month study period. Patient
data will be collected retrospectively from national data
registries, the hospital system and from patient records.
Ethics and dissemination: The Regional Committee for
Medical and Health Research Ethics and Local Patient
Protection Officers in all hospitals have approved the study.
Patients will be informed about the ongoing study on a general
basis with ads on posters and flyers.
Trial registration number NCT04722588. |
---|---|
ISSN: | 2044-6055 2044-6055 |
DOI: | 10.1136/bmjopen-2021-049645 |